SleepCited

Melatonin in sleep disorders.

J J Poza, M Pujol, J J Ortega-Albás, O Romero, Insomnia Study Group of the Spanish Sleep Society (SES)
Review Neurologia 2022 47 인용

연구 설계

연구 유형
Review
대상 집단
Patients with insomnia, particularly older adults with age-related melatonin decline (narrative review)
중재
Melatonin in sleep disorders. Melatonin (various doses and preparations; dosing not clearly defined in literature)
대조군
Placebo
일차 결과
Sleep quality improvement in insomnia; age-related sleep disorders
효과 방향
Neutral
비뚤림 위험
Unclear

초록

Melatonin is the main hormone involved in the control of the sleep-wake cycle. It is easily synthesisable and can be administered orally, which has led to interest in its use as a treatment for insomnia. Moreover, as production of the hormone decreases with age, in inverse correlation with the frequency of poor sleep quality, it has been suggested that melatonin deficit is at least partly responsible for sleep disorders. Treating this age-related deficit would therefore appear to be a natural way of restoring sleep quality, which is lost as patients age. However, despite the undeniable theoretical appeal of this approach to insomnia, little scientific evidence is available that supports any benefit of this substitutive therapy. Furthermore, the most suitable dose ranges and pharmaceutical preparations for melatonin administration are yet to be clearly defined. This review addresses the physiology of melatonin, the different pharmaceutical preparations, and data on its clinical usefulness.

요약

Despite the undeniable theoretical appeal of this approach to insomnia, little scientific evidence is available that supports any benefit of this substitutive therapy and the most suitable dose ranges and pharmaceutical preparations for melatonin administration are yet to be clearly defined.

근거 리뷰에서 활용됨